SARS-CoV-2 vertical transmission supports innate fetal protection: A narrative review

IF 2 Q4 VIROLOGY
E. Barnea, N. Di Simone, S. Hayrabedyan, K. Todorova, A. Inversetti, G. Vento, S. Costa
{"title":"SARS-CoV-2 vertical transmission supports innate fetal protection: A narrative review","authors":"E. Barnea, N. Di Simone, S. Hayrabedyan, K. Todorova, A. Inversetti, G. Vento, S. Costa","doi":"10.3389/fviro.2022.972452","DOIUrl":null,"url":null,"abstract":"Prenatal infections that have been exhaustively studied help frame the current Severe Acute Respiratory Syndrome related coronavirus-2 (SARS-CoV-2) pandemic, with the caveat that asymptomatic SARS-CoV-2 infected patients are not tested, while those symptomatic are delivered and/or treated with drug(s) available on-site. Thus, management and therapy are still heterogeneous. SARS-CoV-2 induced respiratory infection remains mostly local, unless severe, which lessens transplacental vertical transmission (VT). Vaccination prior to or during pregnancy significantly changes the prognosis for both the mother and newborn. The virus spread to the fetus can be binding to ACE2 and TMPRSS2 protein receptors. A recent study demonstrated ACE2 and TMPRSS2 fetal expression in the intestine from the second trimester. Most placental infections are subclinical unless severe villitis and apoptosis are observed. The placenta is rarely tested, and it is highly probable that most are positive for the virus, requiring sophisticated diagnostics to document. Other VT modalities, such as vaginal, rectal or through amniotic fluid contamination, are very rare. Therefore, vaginal delivery is preferable when clinically feasible. It has not yet been determined whether the placenta is a shield or if it transmits infection, while, on the other hand, recent data support fetal resilience, which is plausible due to the major difference between the placental and fetal rates of infection: only 3%–5% of documentable VT compared with up to 100% expected placental exposure to viremia. Newborn Polymerase Chain Reaction (PCR) from nasal swab is more practical as an option for VT diagnosis compared to ocular or anal swab, with low yield. The maternal infection leads to antiviral IgG production of 100% in severe cases, which is transferred to the fetus and breast milk. Postpartum-documenting VT is difficult since horizontal viral transmission may be common and minimized by mother/staff/family-preventive measures. Breastfeeding is safe and encouraged because, beyond nutrition, it promotes protective antibody transfer and maternal bonding. Lessons learned from other Betacorona viruses (SARS-CoV and Middle East Respiratory Syndrome related coronavirus [MERS-CoV]) virulence are relevant since mutations can increase or decrease vulnerability. Overall, data support fetal/newborn resilience against SARS-CoV-2 VT. However, viremia monitoring by sensitive tests and assessment for delayed sequelae shown in adults is necessary.","PeriodicalId":73114,"journal":{"name":"Frontiers in virology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fviro.2022.972452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Prenatal infections that have been exhaustively studied help frame the current Severe Acute Respiratory Syndrome related coronavirus-2 (SARS-CoV-2) pandemic, with the caveat that asymptomatic SARS-CoV-2 infected patients are not tested, while those symptomatic are delivered and/or treated with drug(s) available on-site. Thus, management and therapy are still heterogeneous. SARS-CoV-2 induced respiratory infection remains mostly local, unless severe, which lessens transplacental vertical transmission (VT). Vaccination prior to or during pregnancy significantly changes the prognosis for both the mother and newborn. The virus spread to the fetus can be binding to ACE2 and TMPRSS2 protein receptors. A recent study demonstrated ACE2 and TMPRSS2 fetal expression in the intestine from the second trimester. Most placental infections are subclinical unless severe villitis and apoptosis are observed. The placenta is rarely tested, and it is highly probable that most are positive for the virus, requiring sophisticated diagnostics to document. Other VT modalities, such as vaginal, rectal or through amniotic fluid contamination, are very rare. Therefore, vaginal delivery is preferable when clinically feasible. It has not yet been determined whether the placenta is a shield or if it transmits infection, while, on the other hand, recent data support fetal resilience, which is plausible due to the major difference between the placental and fetal rates of infection: only 3%–5% of documentable VT compared with up to 100% expected placental exposure to viremia. Newborn Polymerase Chain Reaction (PCR) from nasal swab is more practical as an option for VT diagnosis compared to ocular or anal swab, with low yield. The maternal infection leads to antiviral IgG production of 100% in severe cases, which is transferred to the fetus and breast milk. Postpartum-documenting VT is difficult since horizontal viral transmission may be common and minimized by mother/staff/family-preventive measures. Breastfeeding is safe and encouraged because, beyond nutrition, it promotes protective antibody transfer and maternal bonding. Lessons learned from other Betacorona viruses (SARS-CoV and Middle East Respiratory Syndrome related coronavirus [MERS-CoV]) virulence are relevant since mutations can increase or decrease vulnerability. Overall, data support fetal/newborn resilience against SARS-CoV-2 VT. However, viremia monitoring by sensitive tests and assessment for delayed sequelae shown in adults is necessary.
SARS-CoV-2垂直传播支持先天胎儿保护:一项叙述性综述
经过详尽研究的产前感染有助于构建当前与严重急性呼吸系统综合征相关的冠状病毒-2 (SARS-CoV-2)大流行,需要注意的是,无症状的SARS-CoV-2感染患者不接受检测,而有症状的患者则在现场使用可用的药物进行运送和/或治疗。因此,管理和治疗仍然是异质的。SARS-CoV-2引起的呼吸道感染大多是局部的,除非严重,这减少了经胎盘垂直传播(VT)。在怀孕前或怀孕期间接种疫苗会显著改变母亲和新生儿的预后。传播给胎儿的病毒可以与ACE2和TMPRSS2蛋白受体结合。最近的一项研究表明,ACE2和TMPRSS2在妊娠中期的肠道中有胎儿表达。大多数胎盘感染是亚临床的,除非观察到严重的绒毛炎和细胞凋亡。很少对胎盘进行检测,大多数胎盘很可能呈病毒阳性,需要复杂的诊断来记录。其他VT方式,如阴道,直肠或通过羊水污染,是非常罕见的。因此,在临床可行的情况下,阴道分娩是可取的。目前尚不清楚胎盘是否起到保护作用或是否传播感染,然而,另一方面,最近的数据支持胎儿的恢复能力,这是合理的,因为胎盘和胎儿的感染率之间存在重大差异:可记录的VT只有3%-5%,而预期胎盘暴露于病毒血症的比例高达100%。与眼拭子或肛门拭子相比,鼻拭子的新生儿聚合酶链反应(PCR)作为VT诊断的一种更实用的选择,但产量低。在严重的情况下,母体感染导致抗病毒IgG产生100%,并转移到胎儿和母乳中。产后记录VT是困难的,因为水平病毒传播可能很常见,并可通过母亲/工作人员/家庭预防措施将其最小化。母乳喂养是安全且受到鼓励的,因为除了营养之外,它还促进保护性抗体转移和母性结合。从其他冠状病毒(SARS-CoV和中东呼吸综合征相关冠状病毒[MERS-CoV])毒力中吸取的经验教训是相关的,因为突变可以增加或减少易感性。总体而言,数据支持胎儿/新生儿对SARS-CoV-2 VT的恢复能力。然而,通过敏感试验监测病毒血症和评估成人的延迟后遗症是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信